Explore the vast range of titles available.

BackgroundHepatocellular carcinoma (HCC) is a significant global cancer burden, with rising incidence and lacking a unified prevention strategy due to complex aetiologies. Viral exposures may shape host immunity via specific reactive viral antigens that could induce immune responses against hepatocarcinogenesis.ObjectiveWe aimed to characterise viral exposure differences between HCC patients and healthy individuals and identify potentially protective viral antigens against HCC.DesignWe profiled pan-viral serological antibody repertoires using a microbial phage library among 2647 study subjects and examined the biological activities of selective viral antigens on blood-derived immune cells from both healthy individuals and HCC patients.ResultWe identified 153 viral antigens with a significantly reduced serological response in HCC patients compared with healthy individuals. We also observed that a higher serological response to 153 viral antigens is associated with better clinical outcomes of patients with chronic liver diseases and HCC. These findings are consistent across different populations across sex, ethnicity and aetiology. We identified a common epitope (CE1) shared among 39% of reactive viral antigens that belong to the rhinovirus and enterovirus families. We demonstrated that CE1 could induce both CD4+ and CD8+ T-cell activation and CD8+ T-cell-mediated HCC cell killing.ConclusionsOur results suggest that past exposures to members of the Enterovirus genus may be advantageous for cancer patients, highlighting the potential for a viral peptide-based HCC vaccine.

We introduce HUNTRESS, a computational method for mutational intratumor heterogeneity inference from noisy genotype matrices derived from single-cell sequencing data, the running time of which is linear with the number of cells and quadratic with the number of mutations. We prove that, under reasonable conditions, HUNTRESS computes the true progression history of a tumor with high probability. On simulated and real tumor sequencing data, HUNTRESS is demonstrated to be faster than available alternatives with comparable or better accuracy. Additionally, the progression histories of tumors inferred by HUNTRESS on real single-cell sequencing datasets agree with the best known evolution scenarios for the associated tumors.

Tumor evolution is driven by various mutational processes, ranging from single-nucleotide variants (SNVs) to large structural variants (SVs) to dynamic shifts in DNA methylation. Current short-read sequencing methods struggle to accurately capture the full spectrum of these genomic and epigenomic alterations due to inherent technical limitations. To overcome that, here we introduce an approach to identify and analyze the genomic and epigenetic events in different stages of tumoral evolution from long-read sequencing of single-cell derived sublines. We then use it to profile 23 sublines of a mouse cutaneous melanoma cell line, characterized with distinct growth phenotypes and treatment responses. We develop a computational framework for harmonization and joint analysis of different variant types in the evolutionary context. Uniquely, our framework enables detection of recurrent amplifications of putative driver genes, generated by independent SVs across different lineages, suggesting parallel evolution. In addition, our approach revealed gradual and lineage-specific methylation changes associated with aggressive clonal phenotypes. We also show our set of phylogeny-constrained variant calls along with openly released sequencing data can be a valuable resource for the development and benchmarking of computational methods.

Cancer is an evolutionary disease that is shaped by mutations and selection. Cancer progression often results in the emergence of distinct tumor cell populations. Advances in single-cell sequencing (SCS) technologies uncovered an unexpected complexity in tumors, underlining the relevance of intratumor heterogeneity to cancer progression and therapeutic resistance. Unfortunately, reconstruction of the tumor progression history from SCS data is complicated by the presence of several types of noise, necessitating the development of sophisticated computational methods for noise reduction. In this thesis, we present computational methods to infer tumor phylogenetic trees (TPT) from DNA or RNA SCS data. First, we present PhISCS, a combinatorial method, for integrating bulk sequencing data with SCS while accounting for the possible existence of mutations affected by undetected copy number aberrations to infer TPT. Next, we present PhISCS-BnB, a fast branch-and-bound algorithm, for computing the most likely TPT from large-scale SCS DNA data with infinitesimal false-positive errors. Then, we introduce HUNTRESS, another provably correct ultra-fast heuristic for reconstructing TPT from large-scale SCS DNA data while accounting for false-positive errors. Finally, we present Trisicell, a toolkit for inferring and validating TPT from profiles of expressed mutations in SCS RNA data. Trisicell is comprised of three computational methods of independent use and interest to assess, integrate and boost available tools for reconstructing tumor progression trees in a scalable and reliable manner. (a) Trisicell-Boost is a booster for phylogeny inference methods allowing them to scale up and handle large and noisy scRNAseq datasets. (b) Trisicell-PartF employs a localized sampling strategy to compute the probability of any user-specified set of cells forming a subclone seeded by one or more (again user-specified) mutations. (c) Trisicell-Cons is devised to compare two or more phylogenies derived from the same single-cell data and build their consensus tree by collapsing the minimum number of their edges so that the resulting trees are isomorphic. All of the aforementioned tools are bundled in a meta-package called scphylo-tools with a unified API that is freely available at https://scphylo-tools.rtfd.io.

Recent studies exploring the impact of methylation in tumor evolution suggest that while the methylation status of many of the CpG sites are preserved across distinct lineages, others are altered as the cancer progresses. Since changes in methylation status of a CpG site may be retained in mitosis, they could be used to infer the progression history of a tumor via single-cell lineage tree reconstruction. In this work, we introduce the first principled distance-based computational method, Sgootr, for inferring a tumor's single-cell methylation lineage tree and jointly identifying lineage-informative CpG sites which harbor changes in methylation status that are retained along the lineage. We apply Sgootr on the single-cell bisulfite-treated whole genome sequencing data of multiregionally-sampled tumor cells from 9 metastatic colorectal cancer patients made available by Bian et al., as well as multiregionally-sampled single-cell reduced-representation bisulfite sequencing data from a glioblastoma patient made available by Chaligne et al.. We demonstrate that the tumor lineages constructed reveal a simple model underlying colorectal tumor progression and metastatic seeding. A comparison of Sgootr against alternative approaches shows that Sgootr can construct lineage trees with fewer migration events and more in concordance with the sequential-progression model of tumor evolution, in time a fraction of that used in prior studies. Interestingly, lineage-informative CpG sites identified by Sgootr are in inter-CpG island (CGI) regions, as opposed to CGI's, which have been the main regions of interest in genomic methylation-related analyses. Sgootr is implemented as a Snakemake workflow, available at https://github.com/algo-cancer/Sgootr.Competing Interest StatementThe authors have declared no competing interest.Footnotes* Manuscript and supplementary materials updated and revised. Author list updated.

Motivation: Recent advances in single cell sequencing (SCS) offer an unprecedented insight into tumor emergence and evolution. Principled approaches to tumor phylogeny reconstruction via SCS data are typically based on general computational methods for solving an integer linear program (ILP), or a constraint satisfaction program (CSP), which, although guaranteeing convergence to the most likely solution, are very slow. Others based on Monte Carlo Markov Chain (MCMC) or alternative heuristics not only offer no such guarantee, but also are not faster in practice. As a result, novel methods that can scale up to handle the size and noise characteristics of emerging SCS data are highly desirable to fully utilize this technology. Results: We introduce PhISCS-BnB, a Branch and Bound algorithm to compute the most likely perfect phylogeny (PP) on an input genotype matrix extracted from a SCS data set. PhISCS-BnB not only offers an optimality guarantee, but is also 10 to 100 times faster than the best available methods on simulated tumor SCS data. We also applied PhISCS-BnB on a large melanoma data set derived from the sub-lineages of a cell line involving 24 clones with 3574 mutations, which returned the optimal tumor phylogeny in less than 2 hours. The resulting phylogeny also agrees with bulk exome sequencing data obtained from in vivo tumors growing out from the same cell line. Availability: https://github.com/algo-cancer/PhISCS-BnB Footnotes * We have removed the list of the mutations at edges of the tree (it was at the end of the previous document) and added them to our Github repository linked in the manuscript (Figure 1 caption).

Recent technological advances in single cell sequencing (SCS) provide high resolution data for studying intra-tumor heterogeneity and tumor evolution. Available computational methods for tumor phylogeny inference via SCS typically aim to identify the most likely perfect phylogeny tree satisfying infinite sites assumption (ISA). However limitations of SCS technologies such as frequent allele dropout or highly variable sequence coverage, commonly result in mutational call errors and prohibit a perfect phylogeny. In addition, ISA violations are commonly observed in tumor phylogenies due to the loss of heterozygosity, deletions and convergent evolution. In order to address such limitations, we, for the first time, introduce a new combinatorial formulation that integrates single cell sequencing data with matching bulk sequencing data, with the objective of minimizing a linear combination of (i) potential false negatives (due to e.g. allele dropout or variance in sequence coverage) and (ii) potential false positives (due to e.g. read errors) among mutation calls, as well as (iii) the number of mutations that violate ISA - to define the optimal sub-perfect phylogeny. Our formulation ensures that several lineage constraints imposed by the use of variant allele frequencies (VAFs, derived from bulk sequence data) are satisfied. We express our formulation both in the form of an integer linear program (ILP) and - for the first time in the context of tumor phylogeny reconstruction - a boolean constraint satisfaction problem (CSP) and solve them by leveraging state-of-the-art ILP/CSP solvers. The resulting method, which we name PhISCS, is the first to integrate SCS and bulk sequencing data under the finite sites model. Using several simulated and real SCS data sets, we demonstrate that PhISCS is not only more general but also more accurate than the alternative tumor phylogeny inference tools. PhISCS is very fast especially when its CSP based variant is used returns the optimal solution, except in rare instances for which it provides an optimality gap. PhISCS is available at https://github.com/haghshenas/PhISCS.

Cancer progression is an evolutionary process driven by the selection of cells adapted to gain growth advantage. We present the first formal study on the adaptation of gene expression in subclonal evolution. We model evolutionary changes in gene expression as stochastic Ornstein-Uhlenbeck processes, jointly leveraging the evolutionary history of subclones and single-cell expression data. Applying our model to sublines derived from single cells of a mouse melanoma revealed that sublines with distinct phenotypes are underlined by different patterns of gene expression adaptation, indicating non-genetic mechanisms of cancer evolution. Interestingly, sublines previously observed to be resistant to anti-CTLA-4 treatment showed adaptive expression of genes related to invasion and non-canonical Wnt signaling, whereas sublines that responded to treatment showed adaptive expression of genes related to proliferation and canonical Wnt signaling. Our results suggest that clonal phenotypes emerge as the result of specific adaptivity patterns of gene expression.

Tumor evolution is driven by various mutational processes, ranging from single-nucleotide variants (SNVs) to large structural variants (SVs) to dynamic shifts in DNA methylation. Current short-read sequencing methods struggle to accurately capture the full spectrum of these genomic and epigenomic alterations due to inherent technical limitations. To overcome that, here we introduce an approach for long-read sequencing of single-cell derived subclones, and use it to profile 23 subclones of a mouse melanoma cell line, characterized with distinct growth phenotypes and treatment responses. We develop a computational framework for harmonization and joint analysis of different variant types in the evolutionary context. Uniquely, our framework enables detection of recurrent amplifications of putative driver genes, generated by independent SVs across different lineages, suggesting parallel evolution. In addition, our approach revealed gradual and lineage-specific methylation changes associated with aggressive clonal phenotypes. We also show our set of phylogeny-constrained variant calls along with openly released sequencing data can be a valuable resource for the development of new computational methods.

Intratumoral heterogeneity (ITH) can promote cancer progression and treatment failure, but the complexity of the regulatory programs and contextual factors involved complicates its study. To understand the specific contribution of ITH to immune checkpoint blockade (ICB) response, we generated single cell-derived clonal sublines from an ICB-sensitive and genetically and phenotypically heterogeneous mouse melanoma model, M4. Genomic and single cell transcriptomic analyses uncovered the diversity of the sublines and evidenced their plasticity. Moreover, a wide range of tumor growth kinetics were observed in vivo , in part associated with mutational profiles and dependent on T cell-response. Further inquiry into melanoma differentiation states and tumor microenvironment (TME) subtypes of untreated tumors from the clonal sublines demonstrated correlations between highly inflamed and differentiated phenotypes with the response to anti-CTLA-4 treatment. Our results demonstrate that M4 sublines generate intratumoral heterogeneity at both levels of intrinsic differentiation status and extrinsic TME profiles, thereby impacting tumor evolution during therapeutic treatment. These clonal sublines proved to be a valuable resource to study the complex determinants of response to ICB, and specifically the role of melanoma plasticity in immune evasion mechanisms.Intratumoral heterogeneity (ITH) can promote cancer progression and treatment failure, but the complexity of the regulatory programs and contextual factors involved complicates its study. To understand the specific contribution of ITH to immune checkpoint blockade (ICB) response, we generated single cell-derived clonal sublines from an ICB-sensitive and genetically and phenotypically heterogeneous mouse melanoma model, M4. Genomic and single cell transcriptomic analyses uncovered the diversity of the sublines and evidenced their plasticity. Moreover, a wide range of tumor growth kinetics were observed in vivo , in part associated with mutational profiles and dependent on T cell-response. Further inquiry into melanoma differentiation states and tumor microenvironment (TME) subtypes of untreated tumors from the clonal sublines demonstrated correlations between highly inflamed and differentiated phenotypes with the response to anti-CTLA-4 treatment. Our results demonstrate that M4 sublines generate intratumoral heterogeneity at both levels of intrinsic differentiation status and extrinsic TME profiles, thereby impacting tumor evolution during therapeutic treatment. These clonal sublines proved to be a valuable resource to study the complex determinants of response to ICB, and specifically the role of melanoma plasticity in immune evasion mechanisms.